This is a phase 2/3 open label, multicenter trial testing blinatumomab monotherapy for the
treatment of subjects with Relapsed/Refractory (R/R) aggressive B-NHL not achieving CMR after
2 cycles of standard platinum-based chemotherapy regimens administered as S1. This study
incorporates multiple interim analyses for futility, efficacy, and unblinded sample-size
re-estimation. In the phase 3 part of the study, blinatumomab will be compared to
Investigator's Choice chemotherapy.
In March 2019, decision made to not proceed with phase 3.